Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Vistin Pharma ASA ( (DE:VP4) ) is now available.
Vistin Pharma ASA reported a positive financial performance for the second quarter of 2025, with revenues reaching MNOK 118, up from MNOK 106 in the same period last year, driven by a 17% increase in sales volume. The company’s EBITDA also saw an 11% increase, attributed to higher sales and cost improvements, while the net profit for the first half of 2025 rose to MNOK 40.2, reflecting a strong operational focus and shareholder returns with a cash dividend distributed in June.
More about Vistin Pharma ASA
Vistin Pharma ASA is a pharmaceutical company based in Oslo, Norway, focusing on the production and distribution of pharmaceutical products. The company is known for its expertise in the industry and aims to enhance its market position through strategic growth and operational efficiency.
Average Trading Volume: 17,186
Current Market Cap: NOK1.07B
For detailed information about VP4 stock, go to TipRanks’ Stock Analysis page.